美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

NUTRIBAND INC C/WTS (TO PUR COM)

1.30

-0.1000-7.14%

成交量：2,859.00

成交额：3,764.90

市值：1,812.55万

市盈率：-0.42

高：1.37

开：1.37

低：1.30

收：1.40

52周最高：4.50

52周最低：0.8000

股本：1,394.27万

流通股本：1,394.27万

量比：0.87

换手率：0.02%

股息：- -

股息率：- -

每股收益(TTM):-3.0655

净资产收益率：-136.08%

总资产收益率：-55.22%

市净率：2.40

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

新闻稿：Nutriband联合创始人Gareth Sheridan重新担任首席执行官

Nutriband Inc.宣布认股权证以6.43美元行权，筹集资金530.6万美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NTRBW"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NTRBW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTRBW\",,,,,undefined,":{"symbol":"NTRBW","market":"US","secType":"STK","nameCN":"NUTRIBAND INC C/WTS (TO PUR COM)","latestPrice":1.3,"timestamp":1771016400000,"preClose":1.4,"halted":0,"volume":2859,"delay":0,"changeRate":-0.07142857142857134,"floatShares":13942714,"shares":13942714,"eps":-3.0655,"marketStatus":"休市中","change":-0.1,"latestTime":"02-13 16:00:00 EST","open":1.37,"high":1.37,"low":1.3,"amount":3764.9,"amplitude":0.05,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.0655,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1771318800000},"marketStatusCode":7,"adr":0,"listingDate":1633060800000,"exchange":"NASDAQ","adjPreClose":1.4,"volumeRatio":0.8749005821917136},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTRBW\",,,,,undefined,":{"symbol":"NTRBW","floatShares":13942714,"roa":"-55.22%","roe":"-136.08%","lyrEps":0,"volumeRatio":0.8749005821917136,"shares":13942714,"dividePrice":0,"high":1.37,"amplitude":0.05,"preClose":1.4,"low":1.3,"week52Low":0.8,"pbRate":"2.40","psRate":"7.96","week52High":4.5,"institutionHeld":0,"latestPrice":1.3,"eps":-3.0655,"divideRate":0,"volume":2859,"delay":0,"ttmEps":-3.0655,"open":1.37,"prevYearClose":1.61,"prevWeekClose":1.65,"prevMonthClose":1.6,"prevQuarterClose":1.61,"fiveDayClose":1.65,"twentyDayClose":1.65,"sixtyDayClose":1.36},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTRBW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTRBW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NTRBW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTRBW\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1161743016","title":"新闻稿：Nutriband联合创始人Gareth Sheridan重新担任首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=1161743016","media":"投资观察","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161743016?lang=zh_cn&edition=fundamental","pubTime":"2025-10-27 19:06","pubTimestamp":1761563166,"startTime":"0","endTime":"0","summary":"佛罗里达州奥兰多，2025年10月27日——Nutriband Inc.宣布公司创始人Gareth Sheridan已重新担任公司首席执行官。在2025年8月10日至10月27日期间，联合创始人兼董事长Serguei Melnik接管了首席执行官的职责。Sheridan先生即刻恢复首席执行官职务，并将引导公司完成2025年的最终框架，为2026年申请AVERSA芬太尼的目标做好准备。AVERSA芬太尼有潜力成为全球首个旨在防止滥用和误用的滥用防范型阿片类药物贴剂，减少经皮芬太尼贴剂意外暴露的风险。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRB","TM","NTRBW","BK4099","03160","BK4585","BK4588","BK4604","BK4007","BK4555"],"gpt_icon":0},{"id":"1159013021","title":"Nutriband Inc.宣布认股权证以6.43美元行权，筹集资金530.6万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1159013021","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159013021?lang=zh_cn&edition=fundamental","pubTime":"2025-09-04 04:03","pubTimestamp":1756929783,"startTime":"0","endTime":"0","summary":"Nutriband Inc.是一家专注于开发防滥用药物产品的公司，今日宣布其认股权证以每股6.43美元的行权价格被执行，为公司带来530.6万美元的收益。所筹集资金将主要用于AVERSA芬太尼剩余的临床开发工作，以及向FDA提交新药申请以获得市场销售许可。AVERSA芬太尼有潜力成为世界首个具有防滥用特性的阿片类贴剂，预计其在美国的年销售峰值可达8000万至2亿美元。此类前瞻性声明涉及已知和未知的风险及不确定性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTRB","NTRBW","BK4555","TM","BK4099","BK4588","BK4007","BK4585","BK4604","03160"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NTRBW\",params:#limit:6,delay:false,,,undefined,":[]}}